Evaluation of a New Antidiuretic Agent, Desmopressin Acetate (DDAVP)

Kosman, Mary Ellen

doi:10.1001/jama.1978.03290170078039

Cited by 16 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vasopressin has been used over the past 50 years to treat neurogenic (central) diabetes insipidus. A newer agent, desmopressin (a longer duration of action, fewer side‐effects and potentially better efficacy) 26,27 has led to a decline in vasopressin usage in this condition. Vasopressin is used to prevent and treat postoperative abdominal distension, and is also used in abdominal radiography to remove interfering gas shadows.…”

Section: Historical Use Of Vasopressinmentioning

confidence: 99%

Vasopressin

Barlow

2002

Emergency Medicine

View full text Add to dashboard Cite

Section: Historical Use Of Vasopressinmentioning

confidence: 99%

Vasopressin

Barlow

2002

Emergency Medicine

View full text Add to dashboard Cite

“…Vasopressin has been used over the past 50 years to treat neurogenic (central) diabetes insipidus. A newer agent, desmopressin (a longer duration of action, fewer side-effects and potentially better efficacy) 26,27 has led to a decline in vasopressin usage in this condition. Vasopressin is used to prevent and treat postoperative abdominal distension, and is also used in abdominal radiography to remove interfering gas shadows.…”

Section: Historical Use Of Vasopressinmentioning

confidence: 99%

Introduction to ED drugs series

Hughes¹,

Brown²

2002

Emergency Medicine

View full text Add to dashboard Cite

“…Intranasal doses of 10-40~g usually give an antidiuretic effect for about 8 to 10 h, compared to 2-3 h for lysine-vasopressin ( Figure 4). Patients can therefore control their disorder by twice-daily doses (Kosman, 1978).…”

Section: Desmopressinmentioning

confidence: 99%

Review: Clinical Opportunities Provided by the Nasal Administration of Peptides

1993

Journal of Drug Targeting

View full text Add to dashboard Cite

Peptides are rapidly being developed as potential new therapeutic agents and the nasal route is being evaluated as a means of achieving systemic absorption. Current research in man is being directed at a number of polypeptides, including calcitonin, growth hormone releasing hormones (GHRH), insulin, gonadotropin hormone releasing hormones (GnRH) and vasopressin analogues. The underlying protective functions of the nose provide anatomical, temporal and enzymatic barriers to absorption of peptides. The nasal route is relatively unsuccessful when used for high molecular weight polypeptides. Penetration enhancers improve bioavailability but are poorly tolerated. Reproducibility of effect is highly variable, major contributing factors including the site of deposition and type of delivery system as well as changes in the mucous secretion and mucociliary clearance, compounded by the presence of allergy, hay fever and the common cold in treated subjects. The future potential for this route lies in development of effective and well tolerated formulations in highly accurate delivery systems for the chronic administration of peptides, enabling the replacement of impractical and invasive intravenous injections in patients on lifelong substitution treatment for various deficiency states.

show abstract

Evaluation of a New Antidiuretic Agent, Desmopressin Acetate (DDAVP)

Abstract: Desmopressin acetate is a synthetic vasopressin analogue administered by the intranasal route. It is long-acting and well tolerated and may be the agent of choice for treating central diabetes insipidus.

Cited by 16 publications

References 20 publications

Vasopressin

Vasopressin

Introduction to ED drugs series

Review: Clinical Opportunities Provided by the Nasal Administration of Peptides

Contact Info

Product

Resources

About